This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

We evaluated 190 patients in the placebo group of the CHAMPS trial in order to assess factors associated with short-term clinical and brain magnetic resonance imaging (MRI) outcomes in patients with a first clinical demyelinating event involving the optic nerve, spinal cord, or brainstem/cerebellum, and subclinical demyelination on brain MRI. The two study outcomes were 1) development of clinically definite multiple sclerosis (CDMS) and 2) development of CDMS or two or more new or enlarging brain MRI T2 lesions. The presence of gadolinium (Gd)- enhancing lesions on the baseline scan was the only MRI characteristic associated with a higher risk of both the clinical and combined outcomes (p=0.003 and <0.001, respectively). The only demographic or clinical characteristic associated with an increased risk of these outcomes was younger age (p<0.001 for both outcomes). The lowest risk subgroups we could define had a 30% risk of CDMS and a 65% risk of the combined clinical/MRI outcome. Our results indicate that all patients presenting with a first demyelinating event who also have brain MRI evidence of subclinical demyelination have at least a moderate risk of short-term disease activity. This finding provides support for initiating disease-modifying therapy at the time of the first demyelinating event in patients meeting the CHAMPS enrollment criteria.

Key Words: brain MRI • multiple sclerosis

Multiple Sclerosis, Vol. 8, No. 5, 405-409 (2002)
DOI: 10.1191/1352458502ms825oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P O'Connor, R. Kinkel, and M Kremenchutzky Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria Multiple Sclerosis, June 1, 2009; 15(6): 728 - 734. [Abstract] [PDF]

				O. Gonen, T.A. Oberndorfer, M. Inglese, J.S. Babb, J. Herbert, and R.I. Grossman Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2007; 28(2): 267 - 271. [Abstract] [Full Text] [PDF]

				I F Pestalozza, C Pozzilli, S Di Legge, M C Piattella, P Pantano, F Caramia, P Pasqualetti, and G L Lenzi Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome Multiple Sclerosis, August 1, 2005; 11(4): 390 - 394. [Abstract] [PDF]